Business
Passage Bio Presents New Interim Clinical and Biomarker Data for Patients with GM1 Gangliosidosis in Imagine-1 Study at ASGCT 25th Annual Meeting
Longer-term follow-up showed continued developmental improvement for both patients in assessments by study investigators and caregiversInterim safety data at
About this update from Passage Bio, Inc.
[{"type":"text","content":"Longer-term follow-up showed continued developmental improvement for both patients in assessments by study investigators and caregiversInterim safety data at 13 and seven months from patients in Cohort 1 of the Imagine-1 clinical trial showed low dose of PBGM01 was well tolerated and had a favorable safety profileGlobal Phase 1/2 study continues to enroll patients, with interim safety and biomarker data from Cohorts 2 and 3 expected in 2H22 PHILADELPHIA, May 18, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced the presentation of longer-term clinical and biomarker data from Cohort 1 in Imagine-1, a Phase 1/2 study of PBGM01, a gene therapy for GM1 gangliosidosis (GM1). David Weinstein, M.D. M.M.Sc., senior vice president, Clinical Development, Passage Bio, will present the data at 8:30 a.m. ET during a late-breaker oral presentation at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting, being held in Washington, D.C. and virtually. “We continue to be encouraged by the interim data from the first cohort in our Imagine-1 trial and the potential promise it offers for patients. These data show that the low dose of PBGM01 is well-tolerated, has a favorable safety profile and exerts a biological effect that appears to translate to improvement in developmental milestones for these children,” said Mark Forman, M.D., Ph.D., chief medical officer, Passage Bio. “We look forward to continuing to advance the Imagine-1 study through additional cohorts and are excited to gather more data to see the impact of earlier intervention, which we believe may be important based on the initial clinical findings presented to date. The life expectancy for children with GM1 ranges from two to 10 years, so we are eager to pursue the opportunity to potentially offer the first disease-modifying treatment for this disease as quickly as possible.” Key Highlights from Late-Breaker Presentation at ASGCT Include: Low dose PBGM01 was well-tolerated and had a favorable safety profile with patient 1 data through 13 months and patient 2 data through seven months: No serious adverse events, complications related to ICM administration or evidence of dorsal root ganglion (DRG) toxicity were ...